Can Protons or Altered Fractionation Decrease Neurotoxicity after Chemoradiation in Head and Neck Cancer?

Benghiat, Helen; Cashmore, J.; Williams, T.; Green, S.; Hartley, A.; Sanghera, Paul

doi:10.1016/j.clon.2014.09.011

Cited by 4 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others have proposed that a reduction in dose to the posterior fossa achievable with IMPT may result in decreased treatment-related fatigue. 5 However, these dosimetric-based studies have not yet been analyzed to assess whether they do in fact translate to the proposed clinical benefit. A larger dosimetric advantage with proton therapy use is appreciable in the setting of ipsilateral treatment targets, such as salivary tumors or early tonsillar tumors.…”

Section: 5005/jp-journals-10001-1305mentioning

confidence: 99%

Proton Therapy in the Treatment of Head and Neck Cancer

Katsoulakis¹,

Chernichenko²,

Schreiber³

et al. 2017

International Journal of Head and Neck Surgery

View full text Add to dashboard Cite

Aim:To examine the value of proton therapy in relation to other treatment modalities in head and neck cancer.Review: Proton therapy has evolved into more sophisticated and costly intensity-modulated proton therapy and has resulted in even greater dose reduction to normal critical structures at risk as compared with photon therapy. Early clinical studies in head and neck cancers, especially for tumors of the skull base and paranasal sinuses, suggest that proton therapy is excellent in terms of local control and is comparable to intensity-modulated radiation therapy photons but with lower rates of morbidity.Results: There are many potential advantages to radiation therapy with protons. While there are many single institution studies examining the added value of protons to photon therapy, the value of proton therapy must be examined in prospective randomized clinical studies and across many subsites of head and neck cancer. Additional evidence is necessary to guide efficient clinical practice, patient selection, and tumors that are most likely to benefit from this treatment modality and justify proton therapy use given its significant cost.

show abstract

Section: 5005/jp-journals-10001-1305mentioning

confidence: 99%